ID   HSPA9_HUMAN             Reviewed;         679 AA.
AC   P38646; B2RCM1; P30036; P31932; Q1HB43; Q53H23; Q6GU03; Q9BWB7; Q9UC56;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   27-MAY-2002, sequence version 2.
DT   18-JUN-2025, entry version 245.
DE   RecName: Full=Stress-70 protein, mitochondrial {ECO:0000305};
DE            EC=3.6.4.10 {ECO:0000269|PubMed:18632665, ECO:0000269|PubMed:25615450, ECO:0000269|PubMed:30933555, ECO:0000269|PubMed:31177526};
DE   AltName: Full=75 kDa glucose-regulated protein;
DE            Short=GRP-75;
DE   AltName: Full=Heat shock 70 kDa protein 9;
DE   AltName: Full=Heat shock protein family A member 9;
DE   AltName: Full=Mortalin;
DE            Short=MOT;
DE   AltName: Full=Peptide-binding protein 74;
DE            Short=PBP74;
DE   Flags: Precursor;
GN   Name=HSPA9 {ECO:0000312|HGNC:HGNC:5244};
GN   Synonyms=GRP75, HSPA9B, mt-HSP70 {ECO:0000303|PubMed:18632665};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=B-cell;
RX   PubMed=7684501; DOI=10.1128/mcb.13.6.3598-3610.1993;
RA   Domanico S.Z., Denagel D.C., Dahlseid J.N., Green J.M., Pierce S.K.;
RT   "Cloning of the gene encoding peptide-binding protein 74 shows that it is a
RT   new member of the heat shock protein 70 family.";
RL   Mol. Cell. Biol. 13:3598-3610(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7829505; DOI=10.1074/jbc.270.4.1705;
RA   Bhattacharyya T., Karnezis A.N., Murphy S.P., Hoang T., Freeman B.C.,
RA   Phillips B., Morimoto R.I.;
RT   "Cloning and subcellular localization of human mitochondrial hsp70.";
RL   J. Biol. Chem. 270:1705-1710(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT TYR-184.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-74.
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 47-68.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [9]
RP   PROTEIN SEQUENCE OF 47-66.
RC   TISSUE=Mammary gland;
RX   PubMed=7498169; DOI=10.1002/elps.11501601202;
RA   Giometti C.S., Tollaksen S.L., Chubb C., Williams C., Huberman E.;
RT   "Analysis of proteins from human breast epithelial cells using two-
RT   dimensional gel electrophoresis.";
RL   Electrophoresis 16:1215-1224(1995).
RN   [10]
RP   PROTEIN SEQUENCE OF 47-56.
RC   TISSUE=Liver;
RX   PubMed=1286669; DOI=10.1002/elps.11501301201;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RT   "Human liver protein map: a reference database established by
RT   microsequencing and gel comparison.";
RL   Electrophoresis 13:992-1001(1992).
RN   [11]
RP   SEQUENCE REVISION.
RC   TISSUE=Liver;
RX   PubMed=8313870; DOI=10.1002/elps.11501401181;
RA   Hughes G.J., Frutiger S., Paquet N., Pasquali C., Sanchez J.-C.,
RA   Tissot J.-D., Bairoch A., Appel R.D., Hochstrasser D.F.;
RT   "Human liver protein map: update 1993.";
RL   Electrophoresis 14:1216-1222(1993).
RN   [12]
RP   PROTEIN SEQUENCE OF 86-99; 108-121; 160-173; 188-202; 207-234; 349-360;
RP   378-391; 395-405; 469-485; 499-513 AND 542-555, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [14]
RP   IDENTIFICATION IN THE TIM23 COMPLEX.
RX   PubMed=10339406; DOI=10.1006/jmbi.1999.2751;
RA   Bauer M.F., Gempel K., Reichert A.S., Rappold G.A., Lichtner P.,
RA   Gerbitz K.-D., Neupert W., Brunner M., Hofmann S.;
RT   "Genetic and structural characterization of the human mitochondrial inner
RT   membrane translocase.";
RL   J. Mol. Biol. 289:69-82(1999).
RN   [15]
RP   FUNCTION.
RX   PubMed=16091382; DOI=10.1093/intimm/dxh300;
RA   Pilzer D., Fishelson Z.;
RT   "Mortalin/GRP75 promotes release of membrane vesicles from immune attacked
RT   cells and protection from complement-mediated lysis.";
RL   Int. Immunol. 17:1239-1248(2005).
RN   [16]
RP   INTERACTION WITH FXN.
RX   PubMed=17331979; DOI=10.1093/hmg/ddm038;
RA   Shan Y., Napoli E., Cortopassi G.;
RT   "Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and
RT   multiple mitochondrial chaperones.";
RL   Hum. Mol. Genet. 16:929-941(2007).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH
RP   DNLZ.
RX   PubMed=18632665; DOI=10.1074/jbc.m803475200;
RA   Zhai P., Stanworth C., Liu S., Silberg J.J.;
RT   "The human escort protein Hep binds to the ATPase domain of mitochondrial
RT   hsp70 and regulates ATP hydrolysis.";
RL   J. Biol. Chem. 283:26098-26106(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-135; LYS-138; LYS-143; LYS-234;
RP   LYS-288; LYS-300; LYS-567 AND LYS-646, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [19]
RP   INTERACTION WITH HSCB.
RX   PubMed=20668094; DOI=10.1093/hmg/ddq301;
RA   Uhrigshardt H., Singh A., Kovtunovych G., Ghosh M., Rouault T.A.;
RT   "Characterization of the human HSC20, an unusual DnaJ type III protein,
RT   involved in iron-sulfur cluster biogenesis.";
RL   Hum. Mol. Genet. 19:3816-3834(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   FUNCTION.
RX   PubMed=21123823; DOI=10.1182/blood-2010-06-293167;
RA   Chen T.H., Kambal A., Krysiak K., Walshauser M.A., Raju G., Tibbitts J.F.,
RA   Walter M.J.;
RT   "Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in
RT   hematopoietic progenitors in mice.";
RL   Blood 117:1530-1539(2011).
RN   [22]
RP   MALONYLATION AT LYS-206.
RX   PubMed=21908771; DOI=10.1074/mcp.m111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y., He W.,
RA   Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C., Dai J.,
RA   Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [23]
RP   IDENTIFICATION IN THE MINOS/MITOS COMPLEX.
RX   PubMed=22114354; DOI=10.1091/mbc.e11-09-0774;
RA   Alkhaja A.K., Jans D.C., Nikolov M., Vukotic M., Lytovchenko O.,
RA   Ludewig F., Schliebs W., Riedel D., Urlaub H., Jakobs S., Deckers M.;
RT   "MINOS1 is a conserved component of mitofilin complexes and required for
RT   mitochondrial function and cristae organization.";
RL   Mol. Biol. Cell 23:247-257(2012).
RN   [24]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=22002106; DOI=10.1074/mcp.m111.013680;
RA   Ahmad Y., Boisvert F.M., Lundberg E., Uhlen M., Lamond A.I.;
RT   "Systematic analysis of protein pools, isoforms, and modifications
RT   affecting turnover and subcellular localization.";
RL   Mol. Cell. Proteomics 11:M111.013680.01-M111.013680.15(2012).
RN   [25]
RP   INTERACTION WITH TESPA.
RX   PubMed=23501103; DOI=10.1016/j.bbrc.2013.02.099;
RA   Matsuzaki H., Fujimoto T., Tanaka M., Shirasawa S.;
RT   "Tespa1 is a novel component of mitochondria-associated endoplasmic
RT   reticulum membranes and affects mitochondrial calcium flux.";
RL   Biochem. Biophys. Res. Commun. 433:322-326(2013).
RN   [26]
RP   INTERACTION WITH PDPN.
RX   PubMed=23541579; DOI=10.1016/j.bbrc.2013.03.057;
RA   Tsuneki M., Maruyama S., Yamazaki M., Xu B., Essa A., Abe T., Babkair H.,
RA   Cheng J., Yamamoto T., Saku T.;
RT   "Extracellular heat shock protein A9 is a novel interaction partner of
RT   podoplanin in oral squamous cell carcinoma cells.";
RL   Biochem. Biophys. Res. Commun. 434:124-130(2013).
RN   [27]
RP   INTERACTION WITH DNLZ.
RX   PubMed=23462535; DOI=10.1016/j.ijbiomac.2013.02.009;
RA   Dores-Silva P.R., Minari K., Ramos C.H., Barbosa L.R., Borges J.C.;
RT   "Structural and stability studies of the human mtHsp70-escort protein 1: An
RT   essential mortalin co-chaperone.";
RL   Int. J. Biol. Macromol. 56:140-148(2013).
RN   [28]
RP   INTERACTION WITH ISCU.
RX   PubMed=23940031; DOI=10.1074/jbc.m113.482042;
RA   Cai K., Frederick R.O., Kim J.H., Reinen N.M., Tonelli M., Markley J.L.;
RT   "Human mitochondrial chaperone (mtHSP70) and cysteine desulfurase (NFS1)
RT   bind preferentially to the disordered conformation, whereas co-chaperone
RT   (HSC20) binds to the structured conformation of the iron-sulfur cluster
RT   scaffold protein (ISCU).";
RL   J. Biol. Chem. 288:28755-28770(2013).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-87 AND SER-408, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   FUNCTION, INTERACTION WITH TP53 AND UBXN2A, AND SUBCELLULAR LOCATION.
RX   PubMed=24625977; DOI=10.1038/cddis.2014.100;
RA   Sane S., Abdullah A., Boudreau D.A., Autenried R.K., Gupta B.K., Wang X.,
RA   Wang H., Schlenker E.H., Zhang D., Telleria C., Huang L., Chauhan S.C.,
RA   Rezvani K.;
RT   "Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell
RT   death by interfering with the p53-Mortalin interactions in colon cancer
RT   cells.";
RL   Cell Death Dis. 5:e1118-e1118(2014).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-513, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [33]
RP   INVOLVEMENT IN SIDBA4, VARIANTS SIDBA4 PRO-212; SER-388; LYS-415 AND
RP   458-ILE-ASN-459 DEL, AND VARIANTS LEU-200; LYS-539; TRP-573 AND LYS-577.
RX   PubMed=26491070; DOI=10.1182/blood-2015-09-659854;
RA   Schmitz-Abe K., Ciesielski S.J., Schmidt P.J., Campagna D.R., Rahimov F.,
RA   Schilke B.A., Cuijpers M., Rieneck K., Lausen B., Linenberger M.L.,
RA   Sendamarai A.K., Guo C., Hofmann I., Newburger P.E., Matthews D.,
RA   Shimamura A., Snijders P.J., Towne M.C., Niemeyer C.M., Watson H.G.,
RA   Dziegiel M.H., Heeney M.M., May A., Bottomley S.S., Swinkels D.W.,
RA   Markianos K., Craig E.A., Fleming M.D.;
RT   "Congenital sideroblastic anemia due to mutations in the mitochondrial
RT   HSP70 homologue HSPA9.";
RL   Blood 126:2734-2738(2015).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [35]
RP   INVOLVEMENT IN EVPLS, AND VARIANTS EVPLS TRP-126 AND CYS-128.
RX   PubMed=26598328; DOI=10.1038/srep17154;
RA   Royer-Bertrand B., Castillo-Taucher S., Moreno-Salinas R., Cho T.J.,
RA   Chae J.H., Choi M., Kim O.H., Dikoglu E., Campos-Xavier B., Girardi E.,
RA   Superti-Furga G., Bonafe L., Rivolta C., Unger S., Superti-Furga A.;
RT   "Mutations in the heat-shock protein A9 (HSPA9) gene cause the EVEN-PLUS
RT   syndrome of congenital malformations and skeletal dysplasia.";
RL   Sci. Rep. 5:17154-17154(2015).
RN   [36]
RP   FUNCTION, INTERACTION WITH UBXN2A, AND MUTAGENESIS OF THR-441; PRO-442;
RP   LYS-555 AND ILE-558.
RX   PubMed=26634371; DOI=10.1007/s12192-015-0661-5;
RA   Sane S., Abdullah A., Nelson M.E., Wang H., Chauhan S.C., Newton S.S.,
RA   Rezvani K.;
RT   "Structural studies of UBXN2A and mortalin interaction and the putative
RT   role of silenced UBXN2A in preventing response to chemotherapy.";
RL   Cell Stress Chaperones 21:313-326(2016).
RN   [37]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=25615450; DOI=10.1371/journal.pone.0117170;
RA   Dores-Silva P.R., Barbosa L.R., Ramos C.H., Borges J.C.;
RT   "Human mitochondrial Hsp70 (mortalin): shedding light on ATPase activity,
RT   interaction with adenosine nucleotides, solution structure and domain
RT   organization.";
RL   PLoS ONE 10:e0117170-e0117170(2015).
RN   [38]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH FXN; NFU1; NFS1 AND ISCU,
RP   AND MUTAGENESIS OF GLY-489.
RX   PubMed=26702583; DOI=10.1016/j.mito.2015.12.005;
RA   Shan Y., Cortopassi G.;
RT   "Mitochondrial Hspa9/Mortalin regulates erythroid differentiation via iron-
RT   sulfur cluster assembly.";
RL   Mitochondrion 26:94-103(2016).
RN   [39] {ECO:0007744|PDB:4KBO}
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 52-431.
RX   PubMed=24687350; DOI=10.1002/pro.2466;
RA   Amick J., Schlanger S.E., Wachnowsky C., Moseng M.A., Emerson C.C.,
RA   Dare M., Luo W.I., Ithychanda S.S., Nix J.C., Cowan J.A., Page R.C.,
RA   Misra S.;
RT   "Crystal structure of the nucleotide-binding domain of mortalin, the
RT   mitochondrial Hsp70 chaperone.";
RL   Protein Sci. 23:833-842(2014).
RN   [40]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=28848044; DOI=10.1074/jbc.m117.788463;
RA   Srivastava S., Savanur M.A., Sinha D., Birje A., Vigneshwaran R.,
RA   Saha P.P., D'Silva P.;
RT   "Regulation of mitochondrial protein import by the nucleotide exchange
RT   factors GrpEL1 and GrpEL2 in human cells.";
RL   J. Biol. Chem. 292:18075-18090(2017).
RN   [41] {ECO:0007744|PDB:6P2U}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 52-431 IN COMPLEX WITH ADP
RP   ANALOG, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=31177526; DOI=10.1002/1873-3468.13475;
RA   Moseng M.A., Nix J.C., Page R.C.;
RT   "2- and N6-functionalized adenosine-5'-diphosphate analogs for the
RT   inhibition of mortalin.";
RL   FEBS Lett. 593:2030-2039(2019).
RN   [42] {ECO:0007744|PDB:6NHK}
RP   X-RAY CRYSTALLOGRAPHY (2.78 ANGSTROMS) OF 54-429 IN COMPLEX WITH ADP,
RP   FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS EVPLS
RP   TRP-126 AND CYS-128.
RX   PubMed=30933555; DOI=10.1021/acs.jpcb.9b00071;
RA   Moseng M.A., Nix J.C., Page R.C.;
RT   "Biophysical Consequences of EVEN-PLUS Syndrome Mutations for the Function
RT   of Mortalin.";
RL   J. Phys. Chem. B 123:3383-3396(2019).
CC   -!- FUNCTION: Mitochondrial chaperone that plays a key role in
CC       mitochondrial protein import, folding, and assembly. Plays an essential
CC       role in the protein quality control system, the correct folding of
CC       proteins, the re-folding of misfolded proteins, and the targeting of
CC       proteins for subsequent degradation. These processes are achieved
CC       through cycles of ATP binding, ATP hydrolysis, and ADP release,
CC       mediated by co-chaperones (PubMed:18632665, PubMed:25615450,
CC       PubMed:28848044, PubMed:30933555, PubMed:31177526). In mitochondria, it
CC       associates with the TIM (translocase of the inner membrane) protein
CC       complex to assist in the import and folding of mitochondrial proteins
CC       (By similarity). Plays an important role in mitochondrial iron-sulfur
CC       cluster (ISC) biogenesis, interacts with and stabilizes ISC cluster
CC       assembly proteins FXN, NFU1, NFS1 and ISCU (PubMed:26702583). Regulates
CC       erythropoiesis via stabilization of ISC assembly (PubMed:21123823,
CC       PubMed:26702583). Regulates mitochondrial calcium-dependent apoptosis
CC       by coupling two calcium channels, ITPR1 and VDAC1, at the mitochondria-
CC       associated endoplasmic reticulum (ER) membrane to facilitate calcium
CC       transport from the ER lumen to the mitochondria intermembrane space,
CC       providing calcium for the downstream calcium channel MCU, which
CC       releases it into the mitochondrial matrix (By similarity). Although
CC       primarily located in the mitochondria, it is also found in other
CC       cellular compartments. In the cytosol, it associates with proteins
CC       involved in signaling, apoptosis, or senescence. It may play a role in
CC       cell cycle regulation via its interaction with and promotion of
CC       degradation of TP53 (PubMed:24625977, PubMed:26634371). May play a role
CC       in the control of cell proliferation and cellular aging (By
CC       similarity). Protects against reactive oxygen species (ROS) (By
CC       similarity). Extracellular HSPA9 plays a cytoprotective role by
CC       preventing cell lysis following immune attack by the membrane attack
CC       complex by disrupting formation of the complex (PubMed:16091382).
CC       {ECO:0000250|UniProtKB:P0CS90, ECO:0000250|UniProtKB:P38647,
CC       ECO:0000269|PubMed:16091382, ECO:0000269|PubMed:18632665,
CC       ECO:0000269|PubMed:21123823, ECO:0000269|PubMed:24625977,
CC       ECO:0000269|PubMed:25615450, ECO:0000269|PubMed:26634371,
CC       ECO:0000269|PubMed:26702583, ECO:0000269|PubMed:28848044,
CC       ECO:0000269|PubMed:30933555, ECO:0000269|PubMed:31177526}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.10;
CC         Evidence={ECO:0000269|PubMed:18632665, ECO:0000269|PubMed:25615450,
CC         ECO:0000269|PubMed:30933555, ECO:0000269|PubMed:31177526};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066;
CC         Evidence={ECO:0000305|PubMed:18632665};
CC   -!- ACTIVITY REGULATION: The chaperone activity is regulated by ATP-induced
CC       allosteric coupling of the nucleotide-binding (NBD) and substrate-
CC       binding (SBD) domains. ATP binding in the NBD leads to a conformational
CC       change in the NBD, which is transferred through the interdomain linker
CC       (IDL) to the substrate-binding domain (SBD). This elicits a reduced
CC       substrate affinity and a faster substrate exchange rate. Upon
CC       hydrolysis of ATP to ADP, the protein undergoes a conformational change
CC       that increases its affinity for substrate proteins. It cycles through
CC       repeated phases of ATP hydrolysis and nucleotide exchange, facilitating
CC       repeated cycles of substrate binding and release (By similarity).
CC       Functions in collaboration with co-chaperones. Functions with the co-
CC       chaperone, DNLZ, to maintain solubility and regulate ATP hydrolysis
CC       (PubMed:18632665). Nucleotide exchange factors, GRPEL1 and GRPEL2,
CC       accelerate nucleotide exchange (PubMed:28848044).
CC       {ECO:0000250|UniProtKB:P11021, ECO:0000269|PubMed:18632665,
CC       ECO:0000269|PubMed:28848044}.
CC   -!- SUBUNIT: Interacts strongly with the intermediate form of FXN and
CC       weakly with its mature form (PubMed:17331979, PubMed:26702583).
CC       Interacts with HSCB (PubMed:20668094). Associates with the
CC       mitochondrial contact site and cristae organizing system (MICOS)
CC       complex, composed of at least MICOS10/MIC10, CHCHD3/MIC19,
CC       CHCHD6/MIC25, APOOL/MIC27, IMMT/MIC60, APOO/MIC23/MIC26 and QIL1/MIC13.
CC       This complex was also known under the names MINOS or MitOS complex. The
CC       MICOS complex associates with mitochondrial outer membrane proteins
CC       SAMM50, MTX1, MTX2 and DNAJC11, mitochondrial inner membrane protein
CC       TMEM11 and with HSPA9 (PubMed:22114354). Interacts with DNLZ, the
CC       interaction is required to prevent self-aggregation (PubMed:23462535,
CC       PubMed:18632665). Interacts with TESPA1 (PubMed:23501103). Interacts
CC       with PDPN (PubMed:23541579). Interacts with NFU1, NFS1 and ISCU
CC       (PubMed:26702583). Interacts with TP53; the interaction promotes TP53
CC       degradation (PubMed:24625977). Interacts (via SBD domain) with UBXN2A;
CC       the interaction with UBXN2A inhibits HSPA9 interaction with and
CC       degradation of TP53, thereby promotes TP53 translocation to the nucleus
CC       (PubMed:24625977, PubMed:26634371). Interacts with ITPR1 AND VDAC1;
CC       this interaction couples ITPR1 to VDAC1 (By similarity). Component of
CC       the TIM23 mitochondrial inner membrane pre-sequence translocase complex
CC       (PubMed:10339406). {ECO:0000250|UniProtKB:P48721,
CC       ECO:0000269|PubMed:10339406, ECO:0000269|PubMed:17331979,
CC       ECO:0000269|PubMed:18632665, ECO:0000269|PubMed:20668094,
CC       ECO:0000269|PubMed:22114354, ECO:0000269|PubMed:23462535,
CC       ECO:0000269|PubMed:23501103, ECO:0000269|PubMed:23541579,
CC       ECO:0000269|PubMed:23940031, ECO:0000269|PubMed:24625977,
CC       ECO:0000269|PubMed:26634371, ECO:0000269|PubMed:26702583}.
CC   -!- INTERACTION:
CC       P38646; Q9H6A0: DENND2D; NbExp=3; IntAct=EBI-354932, EBI-10307465;
CC       P38646; P00533: EGFR; NbExp=5; IntAct=EBI-354932, EBI-297353;
CC       P38646; Q8TDU6: GPBAR1; NbExp=3; IntAct=EBI-354932, EBI-2806519;
CC       P38646; Q9HAV7: GRPEL1; NbExp=5; IntAct=EBI-354932, EBI-1043499;
CC       P38646; Q8IWL3: HSCB; NbExp=14; IntAct=EBI-354932, EBI-1805738;
CC       P38646; Q8WX92: NELFB; NbExp=2; IntAct=EBI-354932, EBI-347721;
CC       P38646; Q99650: OSMR; NbExp=4; IntAct=EBI-354932, EBI-2804080;
CC       P38646; P04637: TP53; NbExp=6; IntAct=EBI-354932, EBI-366083;
CC       P38646; O15350: TP73; NbExp=11; IntAct=EBI-354932, EBI-389606;
CC       P38646; P13693: TPT1; NbExp=4; IntAct=EBI-354932, EBI-1783169;
CC       P38646; A4D2J0: YKT6; NbExp=3; IntAct=EBI-354932, EBI-10173443;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:22002106,
CC       ECO:0000269|PubMed:26702583}. Nucleus, nucleolus
CC       {ECO:0000269|PubMed:22002106, ECO:0000269|PubMed:24625977}. Cytoplasm
CC       {ECO:0000269|PubMed:24625977}. Mitochondrion matrix
CC       {ECO:0000250|UniProtKB:P48721}. Note=Found in a complex with HSPA9 and
CC       VDAC1 at the endoplasmic reticulum-mitochondria contact sites.
CC       {ECO:0000250|UniProtKB:P48721}.
CC   -!- DOMAIN: The N-terminal nucleotide binding domain (NBD) is responsible
CC       for binding and hydrolyzing ATP. The C-terminal substrate-binding
CC       domain (SBD) binds to the client/substrate proteins. The two domains
CC       are allosterically coupled so that, when ATP is bound to the NBD, the
CC       SBD binds relatively weakly to clients. When ADP is bound in the NBD, a
CC       conformational change enhances the affinity of the SBD for client
CC       proteins. {ECO:0000250|UniProtKB:P0DMV8}.
CC   -!- DISEASE: Anemia, sideroblastic, 4 (SIDBA4) [MIM:182170]: A form of
CC       sideroblastic anemia, a bone marrow disorder defined by the presence of
CC       pathologic iron deposits in erythroblast mitochondria. Sideroblastic
CC       anemia is characterized by anemia of varying severity, hypochromic
CC       peripheral erythrocytes, systemic iron overload secondary to chronic
CC       ineffective erythropoiesis, and the presence of bone marrow ringed
CC       sideroblasts. Sideroblasts are characterized by iron-loaded
CC       mitochondria clustered around the nucleus. SIDBA4 has been reported to
CC       be inherited as an autosomal recessive disease, with a pseudodominant
CC       pattern of inheritance in some families. {ECO:0000269|PubMed:26491070}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Even-plus syndrome (EVPLS) [MIM:616854]: An autosomal
CC       recessive syndrome characterized by epiphyseal and vertebral dysplasia,
CC       prenatal-onset short stature, a distinct craniofacial phenotype with
CC       microtia, a flat facial profile with flat nose and triangular nares,
CC       cardiac malformations, and additional findings such as anal atresia,
CC       hypodontia, aplasia cutis, and others. {ECO:0000269|PubMed:26598328,
CC       ECO:0000269|PubMed:30933555}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the heat shock protein 70 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L11066; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; L15189; AAA67526.1; -; mRNA.
DR   EMBL; AK315177; BAG37618.1; -; mRNA.
DR   EMBL; AK222758; BAD96478.1; -; mRNA.
DR   EMBL; DQ531046; ABF50973.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW62129.1; -; Genomic_DNA.
DR   EMBL; BC000478; AAH00478.1; -; mRNA.
DR   EMBL; BC024034; AAH24034.1; -; mRNA.
DR   CCDS; CCDS4208.1; -.
DR   PIR; B48127; B48127.
DR   RefSeq; NP_004125.3; NM_004134.6.
DR   PDB; 3N8E; X-ray; 2.80 A; A/B=439-597.
DR   PDB; 4KBO; X-ray; 2.80 A; A=52-431.
DR   PDB; 6NHK; X-ray; 2.78 A; A/B=54-429.
DR   PDB; 6P2U; X-ray; 2.00 A; A=52-431.
DR   PDB; 6PMT; X-ray; 2.30 A; A=52-431.
DR   PDB; 9BLS; EM; 2.96 A; A=46-639.
DR   PDB; 9BLT; EM; 3.38 A; A=46-639.
DR   PDB; 9BLU; EM; 3.38 A; A=46-559.
DR   PDBsum; 3N8E; -.
DR   PDBsum; 4KBO; -.
DR   PDBsum; 6NHK; -.
DR   PDBsum; 6P2U; -.
DR   PDBsum; 6PMT; -.
DR   PDBsum; 9BLS; -.
DR   PDBsum; 9BLT; -.
DR   PDBsum; 9BLU; -.
DR   AlphaFoldDB; P38646; -.
DR   EMDB; EMD-44675; -.
DR   EMDB; EMD-44676; -.
DR   EMDB; EMD-44677; -.
DR   SMR; P38646; -.
DR   BioGRID; 109545; 757.
DR   ComplexPortal; CPX-6129; TIM23 mitochondrial inner membrane pre-sequence translocase complex, TIM17A variant.
DR   ComplexPortal; CPX-6130; TIM23 mitochondrial inner membrane pre-sequence translocase complex, TIM17B variant.
DR   CORUM; P38646; -.
DR   DIP; DIP-32936N; -.
DR   FunCoup; P38646; 1928.
DR   IntAct; P38646; 235.
DR   MINT; P38646; -.
DR   STRING; 9606.ENSP00000297185; -.
DR   BindingDB; P38646; -.
DR   ChEMBL; CHEMBL4295757; -.
DR   GlyCosmos; P38646; 1 site, 1 glycan.
DR   GlyGen; P38646; 5 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (2 sites).
DR   iPTMnet; P38646; -.
DR   MetOSite; P38646; -.
DR   PhosphoSitePlus; P38646; -.
DR   SwissPalm; P38646; -.
DR   BioMuta; HSPA9; -.
DR   DMDM; 21264428; -.
DR   OGP; P38646; -.
DR   REPRODUCTION-2DPAGE; IPI00007765; -.
DR   jPOST; P38646; -.
DR   MassIVE; P38646; -.
DR   PaxDb; 9606-ENSP00000297185; -.
DR   PeptideAtlas; P38646; -.
DR   ProteomicsDB; 55304; -.
DR   Pumba; P38646; -.
DR   TopDownProteomics; P38646; -.
DR   ABCD; P38646; 8 sequenced antibodies.
DR   Antibodypedia; 646; 769 antibodies from 48 providers.
DR   DNASU; 3313; -.
DR   Ensembl; ENST00000297185.9; ENSP00000297185.3; ENSG00000113013.16.
DR   GeneID; 3313; -.
DR   KEGG; hsa:3313; -.
DR   MANE-Select; ENST00000297185.9; ENSP00000297185.3; NM_004134.7; NP_004125.3.
DR   UCSC; uc003ldf.4; human.
DR   AGR; HGNC:5244; -.
DR   CTD; 3313; -.
DR   DisGeNET; 3313; -.
DR   GeneCards; HSPA9; -.
DR   HGNC; HGNC:5244; HSPA9.
DR   HPA; ENSG00000113013; Low tissue specificity.
DR   MalaCards; HSPA9; -.
DR   MIM; 182170; phenotype.
DR   MIM; 600548; gene.
DR   MIM; 616854; phenotype.
DR   OpenTargets; ENSG00000113013; -.
DR   Orphanet; 260305; Autosomal recessive sideroblastic anemia.
DR   Orphanet; 496751; EVEN-plus syndrome.
DR   VEuPathDB; HostDB:ENSG00000113013; -.
DR   eggNOG; KOG0102; Eukaryota.
DR   GeneTree; ENSGT00920000149123; -.
DR   HOGENOM; CLU_005965_2_1_1; -.
DR   InParanoid; P38646; -.
DR   OMA; MGTDWKI; -.
DR   OrthoDB; 2401965at2759; -.
DR   PAN-GO; P38646; 11 GO annotations based on evolutionary models.
DR   PhylomeDB; P38646; -.
DR   BRENDA; 3.6.4.10; 2681.
DR   PathwayCommons; P38646; -.
DR   Reactome; R-HSA-1268020; Mitochondrial protein import.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-6799198; Complex I biogenesis.
DR   Reactome; R-HSA-8949613; Cristae formation.
DR   Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation.
DR   Reactome; R-HSA-9837999; Mitochondrial protein degradation.
DR   Reactome; R-HSA-9841251; Mitochondrial unfolded protein response (UPRmt).
DR   Reactome; R-HSA-9865881; Complex III assembly.
DR   SignaLink; P38646; -.
DR   SIGNOR; P38646; -.
DR   BioGRID-ORCS; 3313; 790 hits in 1138 CRISPR screens.
DR   CD-CODE; 232F8A39; P-body.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; DEE660B4; Stress granule.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; HSPA9; human.
DR   EvolutionaryTrace; P38646; -.
DR   GeneWiki; HSPA9; -.
DR   GenomeRNAi; 3313; -.
DR   Pharos; P38646; Tchem.
DR   PRO; PR:P38646; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P38646; protein.
DR   Bgee; ENSG00000113013; Expressed in adrenal tissue and 210 other cell types or tissues.
DR   ExpressionAtlas; P38646; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0140275; C:MIB complex; HDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; NAS:ComplexPortal.
DR   GO; GO:0005759; C:mitochondrial matrix; IDA:FlyBase.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0001401; C:SAM complex; HDA:UniProtKB.
DR   GO; GO:0005744; C:TIM23 mitochondrial import inner membrane translocase complex; NAS:ComplexPortal.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB.
DR   GO; GO:0140662; F:ATP-dependent protein folding chaperone; IEA:InterPro.
DR   GO; GO:0031072; F:heat shock protein binding; IBA:GO_Central.
DR   GO; GO:0044183; F:protein folding chaperone; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:UniProtKB.
DR   GO; GO:0036444; P:calcium import into the mitochondrion; ISS:UniProtKB.
DR   GO; GO:0051085; P:chaperone cofactor-dependent protein refolding; IBA:GO_Central.
DR   GO; GO:0030218; P:erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0007007; P:inner mitochondrial membrane organization; IC:UniProtKB.
DR   GO; GO:0006886; P:intracellular protein transport; NAS:ComplexPortal.
DR   GO; GO:0016226; P:iron-sulfur cluster assembly; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0045647; P:negative regulation of erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:1902037; P:negative regulation of hematopoietic stem cell differentiation; IEA:Ensembl.
DR   GO; GO:1903707; P:negative regulation of hemopoiesis; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProt.
DR   GO; GO:0006611; P:protein export from nucleus; IEA:Ensembl.
DR   GO; GO:0042026; P:protein refolding; IBA:GO_Central.
DR   GO; GO:0045646; P:regulation of erythrocyte differentiation; IMP:UniProtKB.
DR   CDD; cd11733; ASKHA_NBD_HSP70_HSPA9; 1.
DR   FunFam; 2.60.34.10:FF:000014; Chaperone protein DnaK HSP70; 1.
DR   FunFam; 3.30.420.40:FF:000020; Chaperone protein HscA homolog; 1.
DR   FunFam; 3.30.30.30:FF:000003; Heat shock protein 9; 1.
DR   FunFam; 3.30.420.40:FF:000004; Molecular chaperone DnaK; 1.
DR   FunFam; 3.90.640.10:FF:000003; Molecular chaperone DnaK; 1.
DR   FunFam; 1.20.1270.10:FF:000011; stress-70 protein, mitochondrial isoform X1; 1.
DR   Gene3D; 1.20.1270.10; -; 1.
DR   Gene3D; 3.30.30.30; -; 1.
DR   Gene3D; 3.30.420.40; -; 2.
DR   Gene3D; 3.90.640.10; Actin, Chain A, domain 4; 1.
DR   Gene3D; 2.60.34.10; Substrate Binding Domain Of DNAk, Chain A, domain 1; 1.
DR   HAMAP; MF_00332; DnaK; 1.
DR   InterPro; IPR043129; ATPase_NBD.
DR   InterPro; IPR012725; Chaperone_DnaK.
DR   InterPro; IPR018181; Heat_shock_70_CS.
DR   InterPro; IPR029048; HSP70_C_sf.
DR   InterPro; IPR029047; HSP70_peptide-bd_sf.
DR   InterPro; IPR013126; Hsp_70_fam.
DR   NCBIfam; NF001413; PRK00290.1; 1.
DR   NCBIfam; NF003520; PRK05183.1; 1.
DR   NCBIfam; TIGR02350; prok_dnaK; 1.
DR   PANTHER; PTHR19375; HEAT SHOCK PROTEIN 70KDA; 1.
DR   Pfam; PF00012; HSP70; 1.
DR   PRINTS; PR00301; HEATSHOCK70.
DR   SUPFAM; SSF53067; Actin-like ATPase domain; 2.
DR   SUPFAM; SSF100920; Heat shock protein 70kD (HSP70), peptide-binding domain; 1.
DR   PROSITE; PS00297; HSP70_1; 1.
DR   PROSITE; PS00329; HSP70_2; 1.
DR   PROSITE; PS01036; HSP70_3; 1.
DR   neXtProt; NX_P38646; -.
DR   PharmGKB; PA162391712; -.
DR   TreeFam; TF105046; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Chaperone; Cytoplasm;
KW   Direct protein sequencing; Disease variant; Dwarfism; Hydrolase;
KW   Methylation; Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Transit peptide.
FT   TRANSIT         1..46
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000269|PubMed:1286669,
FT                   ECO:0000269|PubMed:7498169, ECO:0000269|PubMed:9150948"
FT   CHAIN           47..679
FT                   /note="Stress-70 protein, mitochondrial"
FT                   /id="PRO_0000013563"
FT   REGION          1..432
FT                   /note="Interaction with NFS1"
FT                   /evidence="ECO:0000269|PubMed:26702583"
FT   REGION          63..431
FT                   /note="Nucleotide-binding domain (NBD)"
FT                   /evidence="ECO:0000303|PubMed:24687350"
FT   REGION          432..679
FT                   /note="Interaction with FXN and ISCU"
FT                   /evidence="ECO:0000269|PubMed:26702583"
FT   REGION          432..441
FT                   /note="Interdomain linker"
FT                   /evidence="ECO:0000303|PubMed:24687350"
FT   REGION          442..679
FT                   /note="Substrate-binding domain (SBD)"
FT                   /evidence="ECO:0000303|PubMed:24687350"
FT   REGION          656..679
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        669..679
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         63
FT                   /ligand="ADP"
FT                   /ligand_id="ChEBI:CHEBI:456216"
FT                   /evidence="ECO:0000269|PubMed:30933555,
FT                   ECO:0007744|PDB:6NHK"
FT   BINDING         64
FT                   /ligand="ADP"
FT                   /ligand_id="ChEBI:CHEBI:456216"
FT                   /evidence="ECO:0000269|PubMed:30933555,
FT                   ECO:0007744|PDB:6NHK"
FT   BINDING         313
FT                   /ligand="ADP"
FT                   /ligand_id="ChEBI:CHEBI:456216"
FT                   /evidence="ECO:0000269|PubMed:30933555,
FT                   ECO:0007744|PDB:6NHK"
FT   BINDING         316
FT                   /ligand="ADP"
FT                   /ligand_id="ChEBI:CHEBI:456216"
FT                   /evidence="ECO:0000269|PubMed:30933555,
FT                   ECO:0007744|PDB:6NHK"
FT   BINDING         320
FT                   /ligand="ADP"
FT                   /ligand_id="ChEBI:CHEBI:456216"
FT                   /evidence="ECO:0000269|PubMed:30933555,
FT                   ECO:0007744|PDB:6NHK"
FT   BINDING         388
FT                   /ligand="ADP"
FT                   /ligand_id="ChEBI:CHEBI:456216"
FT                   /evidence="ECO:0000269|PubMed:30933555,
FT                   ECO:0007744|PDB:6NHK"
FT   BINDING         391
FT                   /ligand="ADP"
FT                   /ligand_id="ChEBI:CHEBI:456216"
FT                   /evidence="ECO:0000269|PubMed:30933555,
FT                   ECO:0007744|PDB:6NHK"
FT   MOD_RES         76
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         87
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         135
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         135
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         138
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         138
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         143
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         206
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         206
FT                   /note="N6-malonyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:21908771"
FT   MOD_RES         206
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         234
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         288
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         300
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         300
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         368
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         394
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         408
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         513
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         567
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         567
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         600
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         600
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         610
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         612
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   MOD_RES         646
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         646
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P38647"
FT   VARIANT         74
FT                   /note="Q -> R (in dbSNP:rs17856004)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_046482"
FT   VARIANT         126
FT                   /note="R -> W (in EVPLS; impairs ATP hydrolysis activity.
FT                   Impairs thermostability. Increases the propensity for
FT                   aggregation; dbSNP:rs751478142)"
FT                   /evidence="ECO:0000269|PubMed:26598328,
FT                   ECO:0000269|PubMed:30933555"
FT                   /id="VAR_076662"
FT   VARIANT         127
FT                   /note="R -> G (in dbSNP:rs35091799)"
FT                   /id="VAR_049622"
FT   VARIANT         128
FT                   /note="Y -> C (in EVPLS; impairs ATP hydrolysis activity.
FT                   Impairs thermostability. Increases the propensity for
FT                   aggregation; dbSNP:rs765368797)"
FT                   /evidence="ECO:0000269|PubMed:26598328,
FT                   ECO:0000269|PubMed:30933555"
FT                   /id="VAR_076663"
FT   VARIANT         184
FT                   /note="H -> Y"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_046483"
FT   VARIANT         200
FT                   /note="S -> L (in dbSNP:rs199715716)"
FT                   /evidence="ECO:0000269|PubMed:26491070"
FT                   /id="VAR_076664"
FT   VARIANT         212
FT                   /note="S -> P (in SIDBA4; uncertain significance;
FT                   dbSNP:rs768283289)"
FT                   /evidence="ECO:0000269|PubMed:26491070"
FT                   /id="VAR_076665"
FT   VARIANT         225
FT                   /note="A -> G (in dbSNP:rs34558740)"
FT                   /id="VAR_049623"
FT   VARIANT         388
FT                   /note="G -> S (in SIDBA4; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:26491070"
FT                   /id="VAR_076666"
FT   VARIANT         415
FT                   /note="E -> K (in SIDBA4; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:26491070"
FT                   /id="VAR_076667"
FT   VARIANT         458..459
FT                   /note="Missing (in SIDBA4)"
FT                   /evidence="ECO:0000269|PubMed:26491070"
FT                   /id="VAR_076668"
FT   VARIANT         539
FT                   /note="T -> K"
FT                   /evidence="ECO:0000269|PubMed:26491070"
FT                   /id="VAR_076669"
FT   VARIANT         573
FT                   /note="R -> W (in dbSNP:rs147723579)"
FT                   /evidence="ECO:0000269|PubMed:26491070"
FT                   /id="VAR_076670"
FT   VARIANT         577
FT                   /note="E -> K (in dbSNP:rs905439101)"
FT                   /evidence="ECO:0000269|PubMed:26491070"
FT                   /id="VAR_076671"
FT   MUTAGEN         441
FT                   /note="T->A: No effect on interaction with UBXN2A."
FT                   /evidence="ECO:0000269|PubMed:26634371"
FT   MUTAGEN         442
FT                   /note="P->A: Abolishes interaction with UBXN2A."
FT                   /evidence="ECO:0000269|PubMed:26634371"
FT   MUTAGEN         489
FT                   /note="G->E: Significant loss of interaction with FXN and
FT                   ISCU. Significant increase in interaction with NFS1."
FT                   /evidence="ECO:0000269|PubMed:26702583"
FT   MUTAGEN         555
FT                   /note="K->A: Reduces interaction with UBXN2A."
FT                   /evidence="ECO:0000269|PubMed:26634371"
FT   MUTAGEN         558
FT                   /note="I->A: Abolishes interaction with UBXN2A."
FT                   /evidence="ECO:0000269|PubMed:26634371"
FT   CONFLICT        48
FT                   /note="S -> P (in Ref. 9; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        66
FT                   /note="C -> S (in Ref. 9; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        176
FT                   /note="E -> V (in Ref. 3; BAG37618)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        184
FT                   /note="H -> R (in Ref. 7; AAH00478/AAH24034)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        249
FT                   /note="T -> A (in Ref. 4; BAD96478)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        385
FT                   /note="L -> P (in Ref. 4; BAD96478)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        540
FT                   /note="G -> R (in Ref. 2; AAA67526)"
FT                   /evidence="ECO:0000305"
FT   STRAND          55..59
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          62..71
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          74..77
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          85..88
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          90..93
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          95..97
FT                   /evidence="ECO:0007829|PDB:6NHK"
FT   STRAND          99..102
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           103..106
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   TURN            107..111
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           113..115
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          116..118
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           120..122
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   TURN            123..125
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           131..139
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          142..146
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          150..156
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          159..161
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           163..182
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          188..193
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           199..211
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          215..221
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           222..229
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           232..234
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          236..245
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          250..258
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          261..270
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           275..293
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           298..300
FT                   /evidence="ECO:0007829|PDB:6PMT"
FT   HELIX           302..318
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   TURN            319..321
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          323..334
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          339..347
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           348..354
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           356..360
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           363..372
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   TURN            377..379
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          382..387
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           388..391
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           393..403
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   TURN            413..415
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   HELIX           416..428
FT                   /evidence="ECO:0007829|PDB:6P2U"
FT   STRAND          445..448
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   STRAND          452..458
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   STRAND          463..472
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   STRAND          482..490
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   HELIX           494..496
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   STRAND          497..505
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   STRAND          518..524
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   STRAND          530..536
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   TURN            537..539
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   STRAND          542..548
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   HELIX           555..567
FT                   /evidence="ECO:0007829|PDB:3N8E"
FT   HELIX           569..590
FT                   /evidence="ECO:0007829|PDB:3N8E"
SQ   SEQUENCE   679 AA;  73680 MW;  90969A8D06757753 CRC64;
     MISASRAAAA RLVGAAASRG PTAARHQDSW NGLSHEAFRL VSRRDYASEA IKGAVVGIDL
     GTTNSCVAVM EGKQAKVLEN AEGARTTPSV VAFTADGERL VGMPAKRQAV TNPNNTFYAT
     KRLIGRRYDD PEVQKDIKNV PFKIVRASNG DAWVEAHGKL YSPSQIGAFV LMKMKETAEN
     YLGHTAKNAV ITVPAYFNDS QRQATKDAGQ ISGLNVLRVI NEPTAAALAY GLDKSEDKVI
     AVYDLGGGTF DISILEIQKG VFEVKSTNGD TFLGGEDFDQ ALLRHIVKEF KRETGVDLTK
     DNMALQRVRE AAEKAKCELS SSVQTDINLP YLTMDSSGPK HLNMKLTRAQ FEGIVTDLIR
     RTIAPCQKAM QDAEVSKSDI GEVILVGGMT RMPKVQQTVQ DLFGRAPSKA VNPDEAVAIG
     AAIQGGVLAG DVTDVLLLDV TPLSLGIETL GGVFTKLINR NTTIPTKKSQ VFSTAADGQT
     QVEIKVCQGE REMAGDNKLL GQFTLIGIPP APRGVPQIEV TFDIDANGIV HVSAKDKGTG
     REQQIVIQSS GGLSKDDIEN MVKNAEKYAE EDRRKKERVE AVNMAEGIIH DTETKMEEFK
     DQLPADECNK LKEEISKMRE LLARKDSETG ENIRQAASSL QQASLKLFEM AYKKMASERE
     GSGSSGTGEQ KEDQKEEKQ
//
